| Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer (NCT05244434) | City of Hope Medical Center | 2022-07-03 |
| Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer (NCT05173103) | University of Milano Bicocca | 2021-09-24 |
| Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer (NCT04720664) | Georgetown University | 2021-09-22 |
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer (NCT04498520) | Pamela Munster | 2021-03-31 |
| Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer (NCT04762979) | Marina N Sharifi | 2021-02-12 |
| Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) (NCT04726332) | Exelixis | 2021-02-10 |
| Elacestrant in Preoperative Setting, a Window of Opportunity Study (NCT04797728) | SOLTI Breast Cancer Research Group | 2021-02-09 |
| National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401) | National Cancer Institute (NCI) | 2020-11-11 |
| Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer (NCT04553770) | Jonsson Comprehensive Cancer Center | 2020-10-09 |
| Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study (NCT04316117) | ECOG-ACRIN Cancer Research Group | 2020-09-15 |
| A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer (NCT04505826) | Olema Pharmaceuticals, Inc. | 2020-08-13 |
| Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. (NCT04305834) | City of Hope Medical Center | 2020-03-25 |
| A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (NCT03845166) | Exelixis | 2019-03-20 |
| Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA (NCT05814224) | Centro di Riferimento Oncologico - Aviano | 2018-05-22 |
| A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers (NCT03251378) | Hutchison Medipharma Limited | 2017-12-11 |
| Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (NCT02003209) | National Cancer Institute (NCI) | 2014-02-18 |